Shares of clinical-stage biotech CRISPR Therapeutics(NASDAQ: CRSP)are down an eye-popping 12% as of 12:05 p.m. EDT Wednesday. The biotech's shares sank in response to a patient death in an early stage study assessing the company's off-the-shelf T-cell therapy, CTX110, in patients with CD19+ B-cell malignancies (blood cancers).
Are CRISPR stocks a good investment?
Oct 07, 2021 · The stock is down roughly 8.9% in the month so far. CRSP data by YCharts CRISPR Therapeutics is valued at roughly $7.8 billion and trades …
How to invest in CRISPR?
Nov 04, 2021 · The biotech stock lost ground after the company published weaker-than-expected trial results for one of its key clinical therapies. CRSP data by YCharts. CRISPR published phase 1 trial results for...
What is CRSP stock?
Dec 05, 2021 · CRISPR Therapeutics stock has continued to fall in early December trading. The company's share price is down roughly 6.9% in the month so far: CRSP data by YCharts .
How do you use CRISPR?
Jan 08, 2022 · CRISPR stock has continued to lose ground early in 2022's trading. The company's share price is down roughly 11% in January's trading so far. CRSP data by YCharts
What happened to Crispr stocks?
What happened. CRISPR Therapeutics ( CRSP -3.30% ) stock sank by 15.9% in January, according to data from S&P Global Market Intelligence, amid a surge of bearish momentum impacting the broader market. An assortment of risk factors last month led investors to sell stocks lower.Feb 8, 2022
Is Crispr stock a good investment?
Yes, CRISPR Therapeutics boasts explosive upside potential, but it also comes with a decent amount of risk, more so than many investors can handle.Mar 16, 2022
Is Crispr overvalued?
Many CRISPR gene editing stocks have been overvalued, although share prices have dropped quite a bit.Jan 28, 2022
Who won the CRISPR patent?
In 2020, Doudna and Charpentier shared the Nobel Prize in Chemistry for discovering CRISPR–Cas9 gene editing — but patents and Nobel prizes are not necessarily judged by the same criteria.Mar 9, 2022
Does CRISPR stock pay dividends?
CRSP does not currently pay a dividend.Mar 23, 2022
Will Vertex buy Crispr?
Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics. The biotech firm Vertex Pharmaceuticals is paying $900 million to CRISPR Therapeutics for rights to 60% of the profits from sales of a gene-editing therapy called CTX001.Apr 20, 2021
Is Crispr undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be fairly valued. Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of CRSP, demonstrate its potential to perform inline with the market.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) slid 18.4% in October, according to data from S&P Global Market Intelligence. The biotech stock lost ground after the company published weaker-than-expected trial results for one of its key clinical therapies.
So what
While CRISPR Therapeutics framed the results as positive, the tested efficacy levels for CTX110 appear to have fallen short of the market's expectations. The trial found that CTX110 had a 58% overall response rate and a 38% complete response rate in large B-cell lymphoma. Analysts were mixed on the performance and implications.
Now what
CRISPR stock has regained some ground early in November's trading. The company's share price is up roughly 6% in the month so far.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) sank 12.5% in November, according to data from S&P Global Market Intelligence.
So what
CRISPR Therapeutics published its Q3 results on Nov. 3; it delivered a narrower-than-expected loss, but also sales that fell short of the market's expectations. The company posted a loss of $1.67 per share on revenue of roughly $820,000, while the average analyst estimate had called for a per-share loss of $1.75 on revenue of $1.3 million.
Now what
CRISPR Therapeutics stock has continued to fall in early December trading. The company's share price is down roughly 6.9% in the month so far:
Key Points
Following some stellar gains, investors took a more cautious approach to CRISPR Therapeutics stock in 2021.
What happened
Shares of CRISPR Therapeutics ( NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
So what
CRISPR Therapeutics' drug pipeline revolves around chimeric antigen receptor T-cells (CAR-T) that can be used to target malignant tumors.
Now what
CRISPR stock has continued to lose ground early in 2022's trading. The company's share price is down roughly 11% in January's trading so far.
What happened
CRISPR Therapeutics ( CRSP -0.55% ) stock sank by 15.9% in January, according to data from S&P Global Market Intelligence, amid a surge of bearish momentum impacting the broader market.
NASDAQ: CRSP
An assortment of risk factors last month led investors to sell stocks lower. Macroeconomic concerns, including high inflation, the Federal Reserve's plan to raise interest rates in response, and climbing yields for Treasury bonds, made investors more cautious.
So what
The S&P 500 ended January down 5.3%, and the Nasdaq Composite sank by 9%. Both indexes entered correction territory as investors surveyed mounting risk factors and took money off the table.
Now what
Thus far in February, CRISPR stock has headed even lower -- it's down by another 6.9%. But there was a bit of good news for shareholders recently.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What happened
Shares of the three leading companies developing human therapeutics based on CRISPR gene-editing technology fell as much as 11.4% today. There was no new news that could be interpreted as detrimental to CRISPR Therapeutics (NASDAQ: CRSP), Editas Medicine (NASDAQ: EDIT), or Intellia Therapeutics (NASDAQ: NTLA).
So what
On July 16, scientists published a study in Nature Biotechnology demonstrating that using CRISPR tools to edit faulty DNA sequences can lead to unintended deletions and rearrangements of genetic material. The lead author, Dr. Allan Bradley, issued a cautious summary of the study: